文献速递泌尿生殖与妇科肿瘤放疗放疗物理与技术

立体定向体部放疗治疗合并炎症性肠病的前列腺癌患者

Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease.
PubMed 文献 · Radiat Oncol · 2021-07-09

该研究基于大型机构数据库(n=4245)接受SBRT治疗前列腺腺癌的患者,识别出31例治疗前合并炎症性肠病(IBD)的患者。中位随访期间未观察到生化复发,高级别急性和晚期毒性罕见(仅1例3级直肠炎),任何胃肠道毒性的中位时间为22个月。结论认为现代放疗技术似乎减轻了IBD患者胃肠道副作用的风险,但治疗时仍需谨慎。

要点

  • 31例合并IBD的前列腺癌患者接受5次SBRT,未观察到生化复发。
  • 高级别急性和晚期毒性罕见,仅1例3级直肠炎。
  • 任何胃肠道毒性中位时间22个月,最常见低级别毒性为痔疮发作(n=3)。

核心结论

  • 这是目前最大的IBD合并前列腺癌放疗队列之一,也是唯一的SBRT综述,现代放疗技术似乎减轻了胃肠道副作用风险,但治疗仍需谨慎。

研究设计与样本

  • 回顾性机构数据库研究,从4245例接受SBRT的前列腺腺癌患者中识别出31例治疗前合并IBD的患者。
  • 所有患者均接受5次SBRT,使用机器人放射外科平台和金标追踪。

主要发现

  • IBD队列中大多数(n=18)为溃疡性结肠炎,并使用局部类固醇栓剂治疗IBD。
  • 早期随访中未观察到生化复发。
  • 高级别急性和晚期毒性罕见(n=1,3级直肠炎),任何胃肠道毒性的中位时间为22个月。
  • 最常见的低级别毒性为痔疮发作(n=3)。

关键数值与推荐

  • 急性与晚期毒性采用CTCAE 5.0版评估。
  • 基线IBD特征包括IBD亚型、SBRT前IBD药物和EPIC肠道问卷被回顾。

临床怎么用

  • 对合并IBD的前列腺癌患者,现代SBRT技术可安全有效地实施,但需谨慎并密切监测胃肠道毒性。

局限性

  • 样本量小(n=31),随访时间短,为回顾性研究。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Historically, IBD has been thought to increase the underlying risk of radiation related toxicity in the treatment of prostate cancer. In the modern era, contemporary radiation planning and delivery may mitigate radiation-related toxicity in this theoretically high-risk cohort. This is the first manuscript to report clinical outcomes for men diagnosed with prostate cancer and underlying IBD curatively treated with stereotactic body radiation therapy (SBRT). METHODS: A large institutional database of patients (n = 4245) treated with SBRT for adenocarcinoma of the prostate was interrogated to identify patients who were diagnosed with underlying IBD prior to treatment. All patients were treated with SBRT over five treatment fractions using a robotic radiosurgical platform and fiducial tracking. Baseline IBD characteristics including IBD subtype, pre-SBRT IBD medications, and EPIC bowel questionnaires were reviewed for the IBD cohort. Acute and late toxicity was evaluated using the CTCAE version 5.0. RESULTS: A total of 31 patients were identified who had underlying IBD prior to SBRT for the curative treatment of prostate cancer. The majority (n = 18) were diagnosed with ulcerative colitis and were being treated with local steroid suppositories for IBD. No biochemical relapses were observed in the IBD cohort with early follow up. High-grade acute and late toxicities were rare (n = 1, grade 3 proctitis) with a median time to any GI toxicity of 22 months. Hemorrhoidal flare was the most common low-grade toxicity observed (n = 3). CONCLUSION: To date, this is one of the largest groups of patients with IBD treated safely and effectively with radiation for prostate cancer and the only review of patients treated with SBRT. Caution is warranted when delivering therapeutic radiation to patients with IBD, however modern radiation techniques appear to have mitigated the risk of GI side effects.

来源:Radiat Oncol,查看原文。版权归原作者所有。

引用

  1. Lischalk JW, Blacksburg S, Mendez C, et al. Stereotactic body radiation therapy for the treatment of localized prostate cancer in men with underlying inflammatory bowel disease. Radiat Oncol. 2021. PMID: 34243797. doi:10.1186/s13014-021-01850-1

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。